Head-to-head
Tirzepatide vs 5-Amino-1MQ
A field-by-field comparison of Tirzepatide and 5-Amino-1MQ drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as metabolic compounds, so the useful question is how they differ within that category.
Tirzepatide vs 5-Amino-1MQ at a glance
| Attribute | Tirzepatide | 5-Amino-1MQ |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence grade | Strong | Limited |
| Also known as | Mounjaro, Zepbound | 5-amino-1-methylquinolinium |
| Chain | 39 amino acid dual GIP/GLP-1 agonist | Small molecule (not strictly a peptide) |
| Mechanism | Activates both GIP and GLP-1 receptors. The added GIP activity appears to improve insulin sensitivity and lipid handling while blunting some of the nausea associated with pure GLP-1 agonism. | Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Blocking it raises intracellular NAD+ and SAM, increasing energy expenditure in fat cells. |
| Reported benefits | Up to ~21% mean weight loss at 15 mg in SURMOUNT-1 · Superior HbA1c reduction versus semaglutide in head-to-head trials · Improvements in sleep apnoea and blood pressure | Reduced fat-cell size in rodent studies · Increased cellular NAD+ · Oral bioavailability — no injections |
| Reported side effects | Nausea · Decreased appetite to the point of undereating · Diarrhoea · Rare pancreatitis | Insomnia if dosed late · Mild GI upset · Unknown long-term profile |
| Half-life | About 5 days | Estimated several hours |
| Administration | Once-weekly subcutaneous injection | Oral capsule |
| Dosing overview | 2.5 mg weekly starting dose, escalating in 2.5 mg steps up to 15 mg | 50–150 mg once daily in the morning |
| Storage | Refrigerated pens; can be at room temperature for up to 21 days per label | Cool, dry place away from light |
| Legal status | FDA-approved and prescription-only. | Sold as a research compound; not an approved drug or dietary supplement. |
Key differences between Tirzepatide and 5-Amino-1MQ
Both are metabolic compounds
Tirzepatide and 5-Amino-1MQ are both indexed under metabolic, so they compete for the same use case rather than complementing each other. Tirzepatide: "A dual incretin agonist that has produced the largest weight reductions yet seen in obesity pharmacotherapy trials." 5-Amino-1MQ: "An orally active NNMT inhibitor grouped with metabolic peptides, studied for fat-cell metabolism and NAD+ preservation."
Mechanism of action
Tirzepatide: Activates both GIP and GLP-1 receptors. The added GIP activity appears to improve insulin sensitivity and lipid handling while blunting some of the nausea associated with pure GLP-1 agonism. 5-Amino-1MQ: Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Blocking it raises intracellular NAD+ and SAM, increasing energy expenditure in fat cells.
Evidence quality is not equal
Tirzepatide carries a Strong evidence grade and 5-Amino-1MQ a Limited grade on this index. The grade describes the quality of published human data, not how well a compound works — Tirzepatide has the better-documented record of the two, and claims made about 5-Amino-1MQ rest on thinner human evidence.
Half-life and dosing frequency
Tirzepatide is listed at about 5 days; 5-Amino-1MQ at estimated several hours. That difference is what drives the reported schedules: 2.5 mg weekly starting dose, escalating in 2.5 mg steps up to 15 mg versus 50–150 mg once daily in the morning
Route of administration
Tirzepatide is administered by once-weekly subcutaneous injection. 5-Amino-1MQ is administered by oral capsule.
Legal and regulatory status differs
Tirzepatide: FDA-approved and prescription-only. 5-Amino-1MQ: Sold as a research compound; not an approved drug or dietary supplement. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
Tirzepatide is stored refrigerated pens; can be at room temperature for up to 21 days per label. 5-Amino-1MQ is stored cool, dry place away from light.
What Tirzepatide and 5-Amino-1MQ have in common
- Category: both listed as Metabolic
Each compound in brief
Tirzepatide
Metabolic · Strong evidence
A dual incretin agonist that has produced the largest weight reductions yet seen in obesity pharmacotherapy trials.
Considerations: Same muscle-preservation caveats as semaglutide · Slow titration is essential · High cost and periodic supply constraints
5-Amino-1MQ
Metabolic · Limited evidence
An orally active NNMT inhibitor grouped with metabolic peptides, studied for fat-cell metabolism and NAD+ preservation.
Considerations: No published human trials · Often stacked with metabolic peptides · Marketed heavily ahead of the evidence
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.